RADX

Radiopharm Theranostics Ltd

Add to Watchlist

Advanced Chart

7.536

+0.496(7.045%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.6799

Open

7.0469

VWAP

7.29

Vol

97.38K

Mkt Cap

59.40M

Low

7.000

Amount

710.20K

EV/EBITDA(TTM)

Total Shares

2.36B

54.10M

EV/OCF(TTM)

P/S(TTM)

20.66

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.

4 Analyst Rating

Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 18.75 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.536

Low

12.00

Averages

18.75

High

30.00

Current: 7.536

Low

12.00

Averages

18.75

High

30.00

Brookline

Kemp Dolliver

Buy

initiated

$18

2025-07-21

Reason

Brookline

Kemp Dolliver

Price Target

$18

2025-07-21

initiated

Buy

Reason

Brookline analyst Kemp Dolliver initiated coverage of Radiopharm with a Buy rating and $18 price target. The clinical stage company's pipeline of radiopharmaceutical candidates features novel combinations of targeting moieties, isotopes, and tumor types and is early stage with six of seven programs at either the preclinical stage or in Phase 1, notes the analyst. The company's most advanced candidate, RAD101, is an imaging candidate for brain metastases that is in a Phase 2b study with data from the first two cohorts expected in Q3, the analyst points out.

JonesResearch

Justin Walsh

Buy

maintain

$30

2025-05-22

Reason

JonesResearch

Justin Walsh

Price Target

$30

2025-05-22

maintain

Buy

Reason

JonesResearch analyst Justin Walsh reiterates a Buy rating on Radiopharm and announced a $30 price target on the U.S. shares. The firm remains "intrigued" by the potential of the company's "diverse" radiopharmaceutical pipeline and believes the market is "dramatically undervaluing the opportunity."

ThinkEquity

NULL -> Buy

initiated

$15

2025-05-12

Reason

ThinkEquity

Price Target

$15

2025-05-12

initiated

NULL -> Buy

Reason

ThinkEquity initiated coverage of Radiopharm with a Buy rating and $15 price target. Radiopharm is a dual-listed, clinical-stage radiopharmaceutical company developing a diversified pipeline of diagnostic and therapeutic agents for solid tumors, the analyst tells investors in a research note. The firm says the company's clinical and preclinical programs are grounded in molecular targets with established biological validation but limited radiopharmaceutical competition.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Radiopharm Theranostics Ltd (RADX.O) is -2.22, compared to its 5-year average forward P/E of -0.58. For a more detailed relative valuation and DCF analysis to assess Radiopharm Theranostics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.58

Current PE

-2.22

Overvalued PE

0.25

Undervalued PE

-1.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.64

Current EV/EBITDA

-1.15

Overvalued EV/EBITDA

-0.35

Undervalued EV/EBITDA

-0.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

80.71

Current PS

235.40

Overvalued PS

160.32

Undervalued PS

1.11

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RADX News & Events

Events Timeline

2025-10-01 (ET)

2025-10-01

08:11:54

Radiopharm Gets DSMC Approval to Move Forward with Phase 1 'HEAT' Trial

2025-07-29 (ET)

2025-07-29

07:35:06

Radiopharm reports FY25 closing cash balance $29.12M

2025-07-28 (ET)

2025-07-28

08:06:36

Radiopharm receives IND approval from US FDA to initiate study of RV-01

News

9.0

10-01Newsfilter

Radiopharm Theranostics Gets Green Light from Data Safety and Monitoring Committee to Fast-Track 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial

9.5

07-29Newsfilter

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

9.0

07-28NASDAQ.COM

Radiopharm Reports FDA Clearance To Initiate First-in-human Phase 1 Trial Of RV-01